Clinical studies are either complete or underway to assess the role of inhibiting APOC3 messenger RNA for FCS [16], for severe hypertriglyceridemia (SHTG, defined as plasma triglyceride levels ≥ 500 mg/dL) [12], and for hypertriglyceridemia (plasma triglyceride levels of 150 to 499 mg/dL) with or without elevated cardiovascular risk [13]. The gene discussed is APOC3; the disease is hypertriglyceridemia.